Hosted on MSN18d
Medtronic announces two-year trial outcomes of Evolut TAVR
Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement ...
Medtronic’s Evolut trial outcome could shift US TAVR market
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
TCTMD1d
What’s in a Name: Is It Time to Choose Between TAVI and TAVR?
With regional differences in which name is used for the aortic fix, some say unity is needed. Others can live with both.
Kalkine Media19d
Medtronic’s SMART Trial Shows Evolut TAVR Outperforms SAPIEN in Key Long-Term Outcomes
Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...
Nasdaq19d
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT ... international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic ...
Medscape8d
Better 5-Year Valve Performance With TAVI Than Surgery
Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
abc2719d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
The SMART two-year data demonstrated that Evolut TAVR continues to show ... Cardiovascular Portfolio at Medtronic. "At two years, we continue to see superior valve performance that we will follow ...